| |  Online-Ressource |
|---|
| Verfasst von: | Schlegel, Patrick [VerfasserIn]  |
|---|
| | Teltschik, Heiko-Manuel [VerfasserIn] |
|---|
| | Pfeiffer, Matthias [VerfasserIn] |
|---|
| | Handgretinger, Rupert [VerfasserIn] |
|---|
| | Schumm, Michael [VerfasserIn] |
|---|
| | Koscielniak, Ewa [VerfasserIn] |
|---|
| | Feuchtinger, Tobias [VerfasserIn] |
|---|
| | Klingebiel, Thomas [VerfasserIn] |
|---|
| | Bader, Peter [VerfasserIn] |
|---|
| | Schlegel, Paul-Gerhardt [VerfasserIn] |
|---|
| | Greil, Johann [VerfasserIn] |
|---|
| | Lang, Peter [VerfasserIn] |
|---|
| Titel: | Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children |
|---|
| Verf.angabe: | Patrick Schlegel, Heiko-Manuel Teltschik, Matthias Pfeiffer, Rupert Handgretinger, Michael Schumm, Ewa Koscielniak, Tobias Feuchtinger, Thomas Klingebiel, Peter Bader, Paul-Gerhard Schlegel, Johann Greil, Peter Lang |
|---|
| E-Jahr: | 2011 |
|---|
| Jahr: | 25 June 2011 |
|---|
| Umfang: | 10 S. |
|---|
| Fussnoten: | Gesehen am 12.10.2022 |
|---|
| Titel Quelle: | Enthalten in: Best practice & research |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1999 |
|---|
| Jahr Quelle: | 2011 |
|---|
| Band/Heft Quelle: | 24(2011), 3, Seite 443-452 |
|---|
| ISSN Quelle: | 1532-1924 |
|---|
| Abstract: | The aim of this pilot study was to evaluate the feasibility of long-term subcutaneous application of low-dose IL-2 in children with malignancies at very high risk of relapse who underwent highly T cell and B cell depleted HLA-identical (MUD) or full haplotype mismatched related hematopoetic stem cell transplantation. We studied 11 patients with acute leukemias/myelodysplastic syndrome and juvenile myelomonocytic leukemia (active disease and/or second stem cell transplantation, n = 8; ≥CR 2, n = 2) and relapsed or progressive Ewings sarcoma (n = 2) who received prophylactic IL-2 treatment for a high probability of disease recurrence after allo-HSCT. Toxicities from IL-2 were transient fever, fatigue and local inflammation. In one patient GvHD grade III with no clear association to IL-2 administration occurred. IL-2 administration was started at median day 57 (range 13-154) post-transplant for a mean duration of 28 days (range 15-250). IL-2 administration clearly increased NK cell activity. 3 of 11 patients (ALL, AML, multifocal Ewings sarcoma) survived with a follow-up of ten years. In conclusion, long-term low-dose IL-2 subcutaneous application is feasible in children due to a low side effect profile even after HLA mismatched transplantation and may be a strategy to prevent relapse in pediatric malignancies with extremely high risk of relapse. |
|---|
| DOI: | doi:10.1016/j.beha.2011.04.007 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.beha.2011.04.007 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S1521692611000430 |
|---|
| | DOI: https://doi.org/10.1016/j.beha.2011.04.007 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Interleukin-2 |
|---|
| | natural killer cell activity |
|---|
| | prevention of relapse |
|---|
| | T cell depleted stem cells |
|---|
| | very high risk malignancies |
|---|
| K10plus-PPN: | 1818780992 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children / Schlegel, Patrick [VerfasserIn]; 25 June 2011 (Online-Ressource)
